Baili Tianheng Unit Panku Capital to Invest USD 5 Million in Connexus Therapeutics for 7.91% Stake
On September 17, 2026, Baili Tianheng (688506) announced that its wholly owned subsidiary Panku Capital Limited plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for USD 5 million.
Upon completion of the capital increase, Baili Tianheng will hold a 7.91% equity interest in Connexus.
Connexus is an innovative drug company focused on the development of small-molecule drugs in the oncology field. All of its pipeline projects are at the preclinical research stage.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is neutral for Pharmaceuticals, with intensity 20/100 and 60% confidence over a long term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.